prophy_effects_sotro_molnup
- Organisation:
- Bennett Institute
- Project:
- Coverage, effectiveness and safety of neutralising monoclonal antibodies or antivirals for non-hospitalised patients with COVID-19
Workspace information
- Branch
- main
- Created
- Created by
- Qing Wen
This is an OpenSAFELY workspace. It represents a working directory for the 91 - Coverage, effectiveness and safety of neutralising monoclonal antibodies or antivirals for non-hospitalised patients with COVID-19 project on all of the secure environments supported by OpenSAFELY.
On each secure environment, the directory includes code from the repository, and the results of running it against real data ("jobs"). Researchers can request jobs are run from this page.
Workspace purpose
Research on the prophylactic effects of Sotrovimab and Molnupiravir focuses on non-hospitalised patients during their first recorded COVID-19 infection. It aims to evaluate and compare the risk of hospitalisation and death due to COVID-19 among high-risk individuals from 60 days after receiving treatment and extending a further six months, serving as the primary outcomes.
Releases
Reports
-
No reports added to this workspace
Monitoring
Honeycomb login required